Optometrists in Swansea, MA Accepting Medicare
3 Optometrists found. Showing 1 - 3
 Robert Paul Duquette, OPTOMETRIST Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1162 Grand Army Hwy, Swansea, MA 02777 Phone: 508-676-3036 Fax: 508-676-3036 |
 Dr. Lisa Gail Smith, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1044 G.a.r. Highway #c, Swansea Vision Center, Swansea, MA 02777 Phone: 508-675-7725 Fax: 508-676-3079 |
Frederick R Valentine Jr. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1044 G A R Hwy, Swansea, MA 02777 Phone: 508-675-7725 Fax: 508-676-3079 |
News Archive
Research uncovers SARS-CoV-2 viral traits critical for the virus in human airways
A new study published on the preprint server bioRxiv* in October 2020 reports the discovery of important viral genomic features that are crucial to its replication in the human airway cells, and its enhancing mutations which increase the rate of replication and determine its target cells.
Meflin protein plays a role in restraining progression of pancreatic cancer
A research team led by Nagoya University has revealed that cells containing a protein called Meflin have a role in restraining the progression of pancreatic cancer, a type of cancer that is hard to treat with traditional anti-cancer drugs.
Effectiveness of Mediterranean diet confirmed for chronic disease prevention
It is effective in chronic diseases such as cardiovascular diseases, cancer, diabetes, hypertension or osteoporosis. Experts have insisted that it is possible to prevent 80% cardiovascular diseases and 40% different types of cancer through diet, physical exercise and other healthy habits. Scientists of the UGR are specifically analysing how cells react against aggressions which cause pancreatic alterations and result in cancer.
Arrowhead, Axolabs enter into RNAi therapeutics strategic agreement
Arrowhead Research Corporation, a nanomedicine company with development programs in RNAi therapeutics and obesity, and Axolabs GmbH, a custom research organization offering preclinical solutions and consultancy in the field of oligonucleotide therapeutics, today announced that they have entered into a Strategic Alliance and Master Services Agreement.
FDA issues emergency use authorization for peramivir anti-viral drug
BioCryst Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA), in response to a request from the U.S. Centers for Disease Control and Prevention (CDC), has issued an emergency use authorization (EUA) for the investigational anti-viral drug intravenous (i.v.) peramivir in certain adult and pediatric patients with confirmed or suspected 2009 H1N1 influenza infection who are admitted to a hospital.
› Verified 4 days ago
Physical Therapists
Chiropractors
Speech-Language Pathologists
Occupational Therapists
Optometrists
Podiatrists